长江流域6城市157家医院2007年调脂药物利用分析

Analysis on antilipemic agents used in 157 hospitals of 6 cities in Yangtze River valley in 2007

目的探讨长江流域6城市157家入网医院2007年调脂药物利用情况与发展趋势。方法对长江流域157家入网医院2007年应用调脂药物的种类、销售金额及用药频度等进行分析排序。结果2007年长江流域157家医院调脂药的销售金额同比增长32.76%。2007年入网医院调脂药销售总金额为16676.60万元,其中他汀类药物占总销售金额的72.73%。6城市销售金额及用药频度排序中主要包括阿托伐他汀、辛伐他汀、血脂康、非诺贝特。结论他汀类药物占调脂治疗的主导地位,辛伐他汀、阿托伐他汀为6城市最常使用的品种。以血脂康为代表的中成药销售前景看好。

AIM To evaluate the utilization and development tendency of antilipemic agents in internet 157 hospitals of 6 cities in the Yangtze River valley. METHODS The use of antilipemic agents in 157 hospitals of 6 cities in 2007 were analyzed and arranged in column order statistically in terms of drug varieties, consumption and DDDs. RESULTS The total annual sale cost of the antilipemic agents used in 6 cities was 0.167 billion yuan in 2007, increasing by 32.76% than that in 2006 including the average consumption of the statins accounted for 72.73%. Atorvastatin, simvastatin, Xuezhikang, and fenofibrate dominated in the ranking of cost consumption and DDDs. CONCLUSION The statins are the dominant drug in treatment for hyperlipoidemia. And the potential market requirement is enormous for Xuezhikang and other Chinese traditional patent medicines.